A Phase 1/2 Study of MRTX1133 in People With Solid Tumors That Have a KRAS G12D Gene Mutation


Full Title

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1133 in Patients with Advanced Solid Tumors Harboring a KRAS G12D Mutation


The purpose of this study is to find the best dose of MRTX1133 for people with advanced solid tumors. The people in this study have cancer that keeps growing even after treatment. In addition, their tumors have a mutation (change or variant) in the KRAS gene called G12D.

MRTX1133 is designed to block the mutated KRAS G12D protein in cancer cells. By blocking this protein, MRTX1133 may slow or stop the growth of your cancer. MRTX1133 is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have a solid tumor that has kept growing after treatment and has the KRAS G12D mutation.
  • Have cancer that has spread (metastasized) or cannot be taken out with surgery.
  • Have recovered from the serious side effects of previous treatments before you take MRTX1133.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.


For more information and to see if you can join this study, please call 646-888-4226.




Phase I/II (phases 1 and 2 combined)

Disease Status

Relapsed or Refractory

ClinicalTrials.gov ID